Histocompatibility leucocyte antigen E (HLA-E) and its cognate inhibitory receptor NKG2A could serve as a novel immune checkpoint to be targeted for inducing anti-tumor immunity (Borst et al., 2020). Here, KLRC1 is linked to neoplasm.